Exendin‑4 promotes osteogenic differentiation of adipose‑derived stem cells and facilitates bone repair.
Deng B., Zhu W., Duan Y., Hu Y., Chen X., Song S.
Animal Study, published in Mol Med Rep (2019) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Mol Med Rep (2019)
- Country
- Greece
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 31661134
- PMCID
- PMC6854547
- DOI
- 10.3892/mmr.2019.10764
- Citations
- 15
Abstract (original English)
Inflammation‑related bone defects pose a heavy burden on patients and orthopedic surgeons. Although stem‑cell‑based bone repair has developed rapidly, it is of great significance to characterize bio‑active molecules that facilitate bone regeneration. It is reported that a glucagon‑like peptide 1 receptor agonist, exendin‑4, promoted bone regeneration mediated by the transplantation of adipose‑derived stem cells in a metaphyseal defect mouse model of femur injury. However, the underlying mechanism is unclear. Bone imaging, immunohistochemistry real‑time PCR and western blot analysis were used in the present study, and the results revealed that exendin‑4 increased the transcription of the osteogenic differentiation‑related genes and induced osteogenic differentiation in situ. Furthermore, the present data obtained from sorted adipose‑derived stem cells revealed that exendin‑4 promoted osteogenic differentiation and inhibited adipogenic differentiation in vitro. These findings indicated that exendin‑4 facilitates osteogenic differentiation of transplanted adipose‑derived stem cells for bone repair and illuminated clinical prospects of both adipose‑derived stem cells and exendin‑4 in stem‑cell‑based bone defect repair.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.